# Insmed share price today (Insmed Incorporated, INSM)

> Insmed Incorporated's share price, valuation and earnings point in different directions. The next one or two quarters should make it clearer. INSM · Healthcare · Biotechnology · data as of 4 November 2026. Page: https://www.sectoralpha.in/us/stocks/insm

Sector Alpha also publishes a daily newsletter that explains one Indian stock at a time: https://newsletter.sectoralpha.in/?utm_source=sectoralpha&utm_medium=ai_text&utm_campaign=llms

## Key numbers

- Price: $110.00 (−42.0% in a year)
- Revenue (Jun 2026): ₹0.4 B (+296.1% on a year ago)
- Profit (Jun 2026): ₹0.0 B
- ROE: −173%, FY25

Biggest thing to watch: the price is not yet in a clear uptrend, so timing is the risk more than the business. ## What is the Insmed share price today? Insmed Incorporated's share price was $110.00 at the close on 4 November 2026. It has been falling for 8 weeks. That is 11.7% below its average price over the last 200 trading days. In the last 52 weeks it traded between $93 and $208, and at that close it sat 15% of the way up from that low. Over the past 13 weeks it has done worse than the S&P 500, and it has been behind for 1 week running. Over the last 10 years the share price moved +923% while the S&P 500 moved +261%, so it is ahead of the index over that whole period. It was last ahead over 13 weeks in the week of 30 October 2026. The chart above shows the 13-week comparison for every week. This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row. ## What dividend does Insmed pay? Insmed Incorporated pays no dividend. In the last 12 reported quarters it declared no dividend per share, so there is no payout history to chart and no yield to show. Companies like this usually keep their earnings in the business, so the cash-flow sections show where that cash goes. ## Which stock lists is Insmed on? Insmed is not in the Nasdaq 100, the S&P 500 or the Dow Jones 30, and is not on the US tech stocks list. ## Is Insmed profitable? Insmed Incorporated posted a net loss of ₹0.01 B in the Jun 2026 quarter. The full FY25 year was a loss of ₹1.3 B. That loss is 3.1% of the quarter's revenue. The same quarter a year earlier lost ₹0.3 B. 12 of the last 12 reported quarters were loss-making. Jun 2026 profit was ₹0.0 B. This company reports in its home currency, not US dollars, so the money charts are left out here. The figures in the text are in that currency (₹); nothing is converted. ## How much revenue does Insmed make, and is it growing? Insmed Incorporated reported ₹0.4 B of revenue in the Jun 2026 quarter, +296.1% on the same quarter a year earlier. That is the 12th quarter in a row with growth on the year before. Over 4 years it has grown 33.9% a year on average. The last full year, FY25, came in at ₹0.6 B. The last four reported quarters add to ₹1.1 B. FY25 revenue was ₹0.6 B, +66.7% on the year before. Recent pace: the last four quarters grew +182.7% on average, against 33.9% a year over the longer run, so this year is growing faster than its own long-run rate. Is growth speeding up? Revenue over the last 12 months grew +185.8%, against +86.1% a year over the last 8 quarters (accelerating). This company reports in its home currency, not US dollars, so the money charts are left out here. The figures in the text are in that currency (₹); nothing is converted. ## How much of its sales does Insmed keep? Insmed Incorporated has almost no sales yet: FY25 revenue was ₹0.6 B. On sales that small an operating margin is not a useful reading, so this section is left out until sales grow. ## Is Insmed's profit turning into cash? Insmed Incorporated's cash-flow history is too short to judge how much of its profit turns into cash. In FY25 its operations used ₹0.9 B of cash, against −₹1.3 B of profit. After ₹0.0 B of spending on assets, free cash was −₹1.0 B: it spent more than its operations brought in. Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year. What to look at next: it spends almost nothing on new assets, so the cash goes on running the business. The next section shows the spending figures. This company reports in its home currency, not US dollars, so the money charts are left out here. The figures in the text are in that currency (₹); nothing is converted. ## Where does Insmed's cash go? Insmed Incorporated does not report the customer, stock and supplier day counts a cash cycle needs, so this section looks at its spending on assets instead. It spent ₹0.0 B on assets over the last 3 years. Nothing is estimated in place of the missing day counts, so no cash-cycle chart is drawn. Spending on assets: ₹0.0 B over the last 3 years. In short: almost nothing is being spent on new assets, so the cash goes on running the business. This company reports in its home currency, not US dollars, so the money charts are left out here. The figures in the text are in that currency (₹); nothing is converted. ## What is Insmed's P/E ratio, and how does it compare with its own history? Insmed Incorporated has no P/E right now, because its earnings are negative. The revenue and margin sections are where a turn would show first. The P/E comes back here once profit turns positive. ## Is the Insmed business getting better or worse? Insmed Incorporated's business trend cannot be read yet. There are fewer than eight usable quarters of growth figures, so there is not enough history to read the trend. This is based on 12 quarters of 2 measures, with some gaps. Why it matters: with too little history, we say so rather than guess a direction. The return figures here are yearly, not quarterly. They show level and direction only; they can support the growth lines but never decide the reading alone. There are fewer than eight usable quarters, so this page does not guess a direction from so little history. ## How much does Insmed earn on its capital? Insmed Incorporated earned a ROE of −173% in FY25. That is up from a low of −548% in FY22. Its return on capital used (ROIC) is left out: on sales this small it reads −25%, a number that says nothing useful about the business. ## Does Insmed have too much debt? Insmed Incorporated has total debt of ₹0.7 B against shareholder equity of ₹0.8 B as of Jun 2026, so its debt is 0.98× its equity. Year by year, that ratio went from 1.49 in FY21 to 1.01 in FY25. Keep that borrowing in mind when reading the returns on this page. This company reports in its home currency, not US dollars, so the money charts are left out here. The figures in the text are in that currency (₹); nothing is converted. ## What is the Insmed shareholding pattern? 6.2% of Insmed Incorporated's tradable shares are in short positions, which are bets that the price will fall, so some traders are betting against it. At normal trading volumes, closing those positions would take about 4.8 days. US companies do not publish a quarter-by-quarter list of owners, so this page uses short interest instead. It is a single reading at one point in time; we do not have its history. Why it is at this level: the figure does not say who holds the short positions or why, so we show the level without guessing the story. ## How far is Insmed from balance-sheet trouble? For Insmed Incorporated, the Z-score is 8.99. A Z-score above about 3 is safe and below about 1.8 signals danger, so this is well clear of danger. It estimates how far the balance sheet is from trouble; it is not a forecast of failure. Why it matters: a Z-score of 8.99 is well clear of the danger zone, so the balance sheet is not the risk here. ## How does Insmed rank in its industry? 35.2 out of 100, rank 23 of 30 in Biotechnology, with 61% of the evidence available. Insmed Incorporated scores 35.2 out of 100 against the 30 companies it is compared with in Biotechnology, ranking 23. The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. The four parts add up to the total exactly: 18.6 + 4.5 + 10 + 2.1 = 35.2. This is the same number shown on the industry page; it is worked out once for the whole group and read here. What would change it: The score would fall if profit growth turns negative or margins stop improving while the share price lags its sector. ## Which companies is Insmed compared with? Insmed ranks 23 of 30 Biotechnology companies on the 4-Factor Sector Score, with 35.2 out of 100. 1. [Exelixis, Inc.](https://www.sectoralpha.in/us/stocks/exel) EXEL · breaking out · Most evidence points up · 81% evidence 76.0 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 22.9/35 · Revenue 9.3% · Profit 42.8% · Operating margin change 1.9 points · 83% evidence Capital efficiency 21.0/25 · ROCE 46.5% · Operating margin 39.5% · 76% evidence Valuation 14.4/20 · P/E 15.9× · PEG 0.3 · 65% evidence Relative strength 17.7/20 · Lead over its industry 10.5% · Lead over S&P 500 37% · 1 year 78.3% · 100% evidence · 8 of 12 weeks ahead Exact sum: 22.9 + 21 + 14.4 + 17.7 = 76 · What this means: Earnings, capital efficiency and relative strength all agree. The open questions are about management, upcoming events and risks. 2. [Halozyme Therapeutics, Inc.](https://www.sectoralpha.in/us/stocks/halo) HALO · leader · Most evidence points up · 81% evidence 71.1 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 17.1/35 · Revenue 41.1% · Profit -25.9% · Operating margin change -2.4 points · 83% evidence Capital efficiency 21.0/25 · ROCE 42.3% · Operating margin 59.8% · 76% evidence Valuation 14.4/20 · P/E 22.4× · PEG 0.25 · 65% evidence Relative strength 18.6/20 · Lead over its industry 22.6% · Lead over S&P 500 50.7% · 1 year 91% · 100% evidence · 12 of 12 weeks ahead Exact sum: 17.1 + 21 + 14.4 + 18.6 = 71.1 · What this means: Relative strength against the index is 50.7%, and revenue and profit growth are weak. 3. [Caris Life Sciences, Inc.](https://www.sectoralpha.in/us/stocks/cai) CAI · leader · Most evidence points up · 64% evidence 65.7 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 23.7/35 · Revenue 85.4% · Profit n/a · Operating margin change 20.1 points · 62% evidence Capital efficiency 13.1/25 · ROCE 14.8% · Operating margin 10.2% · 76% evidence Valuation 11.2/20 · P/E -14.2× · PEG n/a · 15% evidence Relative strength 17.7/20 · Lead over its industry 10.2% · Lead over S&P 500 37.4% · 1 year 29.7% · 100% evidence · 12 of 12 weeks ahead Exact sum: 23.7 + 13.1 + 11.2 + 17.7 = 65.7 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 4. [Incyte Corporation](https://www.sectoralpha.in/us/stocks/incy) INCY · turning · Evidence leans up · 71% evidence 64.3 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 26.4/35 · Revenue 26.9% · Profit 85.3% · Operating margin change 16.3 points · 83% evidence Capital efficiency 20.6/25 · ROCE 28.1% · Operating margin 41.9% · 76% evidence Valuation 10.7/20 · P/E 14× · PEG n/a · 15% evidence Relative strength 6.6/20 · Lead over its industry -13.6% · Lead over S&P 500 7.7% · 1 year 15.9% · 100% evidence · 5 of 12 weeks ahead Exact sum: 26.4 + 20.6 + 10.7 + 6.6 = 64.3 · What this means: Earnings are strong; relative strength in its sector is -13.6% and the one-year return is 15.9%. 5. [Genmab A/S](https://www.sectoralpha.in/us/stocks/gmab) GMAB · leader · Evidence leans up · 81% evidence 60.8 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 10.7/35 · Revenue 18.2% · Profit -39.3% · Operating margin change -3.7 points · 83% evidence Capital efficiency 15.7/25 · ROCE 11.7% · Operating margin 35.2% · 76% evidence Valuation 14.9/20 · P/E 21.4× · PEG 0.21 · 65% evidence Relative strength 19.5/20 · Lead over its industry 32.8% · Lead over S&P 500 65.2% · 1 year 92.3% · 100% evidence · 12 of 12 weeks ahead Exact sum: 10.7 + 15.7 + 14.9 + 19.5 = 60.8 · What this means: Relative strength against the index is 65.2%, and revenue and profit growth are weak. 6. [argenx SE](https://www.sectoralpha.in/us/stocks/argx) ARGX · turning · Evidence leans up · 85% evidence 58.8 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 24.7/35 · Revenue 60.6% · Profit 22.4% · Operating margin change 5.9 points · 95% evidence Capital efficiency 16.9/25 · ROCE 18.9% · Operating margin 36.3% · 76% evidence Valuation 9.8/20 · P/E 32× · PEG 1.39 · 65% evidence Relative strength 7.4/20 · Lead over its industry -18.3% · Lead over S&P 500 2.3% · 1 year 9% · 100% evidence · 6 of 12 weeks ahead Exact sum: 24.7 + 16.9 + 9.8 + 7.4 = 58.8 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 7. [Kymera Therapeutics, Inc.](https://www.sectoralpha.in/us/stocks/kymr) KYMR · turning · Evidence leans up · 61% evidence 57.6 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 23.7/35 · Revenue 100% · Profit n/a · Operating margin change 620.5 points · 62% evidence Capital efficiency 6.8/25 · ROCE -22% · Operating margin -116.3% · 76% evidence Valuation 10.0/20 · P/E n/a · PEG n/a · 0% evidence Relative strength 17.1/20 · Lead over its industry 12.3% · Lead over S&P 500 38.4% · 1 year 132.3% · 100% evidence · 7 of 12 weeks ahead Exact sum: 23.7 + 6.8 + 10 + 17.1 = 57.6 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 8. [Vertex Pharmaceuticals Incorporated](https://www.sectoralpha.in/us/stocks/vrtx) VRTX · breaking out · Evidence leans up · 81% evidence 56.1 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 15.9/35 · Revenue 10.2% · Profit 21.1% · Operating margin change -0.8 points · 83% evidence Capital efficiency 19.6/25 · ROCE 20.9% · Operating margin 38.1% · 76% evidence Valuation 10.9/20 · P/E 28.6× · PEG 1.25 · 65% evidence Relative strength 9.7/20 · Lead over its industry -13% · Lead over S&P 500 8.5% · 1 year 34.1% · 100% evidence · 8 of 12 weeks ahead Exact sum: 15.9 + 19.6 + 10.9 + 9.7 = 56.1 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 9. [Spyre Therapeutics, Inc.](https://www.sectoralpha.in/us/stocks/syre) SYRE · quiet · Too little evidence to rank firmly · 56% evidence 55.8 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 23.3/35 · Revenue n/a · Profit n/a · Operating margin change 999.3 points · 52% evidence Capital efficiency 8.6/25 · ROCE -24.5% · Operating margin n/a · 61% evidence Valuation 10.9/20 · P/E -8.2× · PEG n/a · 15% evidence Relative strength 13.0/20 · Lead over its industry 18.5% · Lead over S&P 500 43.8% · 1 year 339.8% · 100% evidence · 4 of 12 weeks ahead Exact sum: 23.3 + 8.6 + 10.9 + 13 = 55.8 · What this means: Some evidence is missing, so the score is pulled toward the middle on purpose. 10. [BeOne Medicines AG](https://www.sectoralpha.in/us/stocks/onc) ONC · leader · Evidence leans up · 64% evidence 54.9 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 22.3/35 · Revenue 34.3% · Profit n/a · Operating margin change 12.4 points · 62% evidence Capital efficiency 13.4/25 · ROCE 13.1% · Operating margin 19.1% · 76% evidence Valuation 9.1/20 · P/E 48.3× · PEG n/a · 15% evidence Relative strength 10.1/20 · Lead over its industry -13.3% · Lead over S&P 500 8.4% · 1 year 17.7% · 100% evidence · 12 of 12 weeks ahead Exact sum: 22.3 + 13.4 + 9.1 + 10.1 = 54.9 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 11. [Moderna, Inc.](https://www.sectoralpha.in/us/stocks/mrna) MRNA · leader · Evidence leans up · 64% evidence 54.7 out of 100 Growth Capital Valuation Relative
12. [Jazz Pharmaceuticals plc](https://www.sectoralpha.in/us/stocks/jazz) JAZZ · quiet · Evidence leans up · 74% evidence 53.6 out of 100 Growth Capital Valuation Relative
13. [Regeneron Pharmaceuticals, Inc.](https://www.sectoralpha.in/us/stocks/regn) REGN · leader · Evidence leans up · 81% evidence 51.9 out of 100 Growth Capital Valuation Relative
14. [Alnylam Pharmaceuticals, Inc.](https://www.sectoralpha.in/us/stocks/alny) ALNY · quiet · Evidence leans up · 64% evidence 51.1 out of 100 Growth Capital Valuation Relative
15. [Royalty Pharma plc](https://www.sectoralpha.in/us/stocks/rprx) RPRX · turning · Evidence leans up · 81% evidence 50.9 out of 100 Growth Capital Valuation Relative
16. [ImmunityBio, Inc.](https://www.sectoralpha.in/us/stocks/ibrx) IBRX · breaking out · Evidence leans down · 61% evidence 49.5 out of 100 Growth Capital Valuation Relative
17. [Protagonist Therapeutics, Inc.](https://www.sectoralpha.in/us/stocks/ptgx) PTGX · losing its lead · Evidence leans down · 74% evidence 49.2 out of 100 Growth Capital Valuation Relative
18. [Bio-Techne Corporation](https://www.sectoralpha.in/us/stocks/tech) TECH · turning · Evidence leans down · 74% evidence 42.2 out of 100 Growth Capital Valuation Relative
19. [Summit Therapeutics Inc.](https://www.sectoralpha.in/us/stocks/smmt) SMMT · breaking out · Too little evidence to rank firmly · 53% evidence 39.7 out of 100 Growth Capital Valuation Relative
20. [Revolution Medicines, Inc.](https://www.sectoralpha.in/us/stocks/rvmd) RVMD · quiet · Too little evidence to rank firmly · 53% evidence 39.5 out of 100 Growth Capital Valuation Relative
21. [Roivant Sciences Ltd.](https://www.sectoralpha.in/us/stocks/roiv) ROIV · turning · Too little evidence to rank firmly · 60% evidence 38.0 out of 100 Growth Capital Valuation Relative
22. [Madrigal Pharmaceuticals, Inc.](https://www.sectoralpha.in/us/stocks/mdgl) MDGL · quiet · Evidence leans down · 61% evidence 36.4 out of 100 Growth Capital Valuation Relative
23. Insmed Incorporated this page INSM · basing · Evidence leans down · 61% evidence 35.2 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 18.6/35 · Revenue 100% · Profit n/a · Operating margin change 212.6 points · 62% evidence Capital efficiency 4.5/25 · ROCE -48.8% · Operating margin -23.8% · 76% evidence Valuation 10.0/20 · P/E n/a · PEG n/a · 0% evidence Relative strength 2.1/20 · Lead over its industry -41.1% · Lead over S&P 500 -24.9% · 1 year -42% · 100% evidence · 7 of 12 weeks ahead Exact sum: 18.6 + 4.5 + 10 + 2.1 = 35.2 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 24. [BridgeBio Pharma, Inc.](https://www.sectoralpha.in/us/stocks/bbio) BBIO · quiet · Most evidence points down · 61% evidence 34.8 out of 100 Growth Capital Valuation Relative
25. [BioNTech SE](https://www.sectoralpha.in/us/stocks/bntx) BNTX · quiet · Most evidence points down · 64% evidence 32.4 out of 100 Growth Capital Valuation Relative
26. [BioMarin Pharmaceutical Inc.](https://www.sectoralpha.in/us/stocks/bmrn) BMRN · quiet · Most evidence points down · 81% evidence 26.7 out of 100 Growth Capital Valuation Relative
27. [Ascendis Pharma A/S](https://www.sectoralpha.in/us/stocks/asnd) ASND · turning · Too little evidence to rank firmly · 44% evidence 63.0 out of 100 Growth Capital Valuation Relative
28. Apogee Therapeutics, Inc. APGE · Too little evidence to rank firmly · 27% evidence 46.7 out of 100 Growth Capital Valuation Relative
29. Nuvalent, Inc. NUVL · Too little evidence to rank firmly · 20% evidence 40.9 out of 100 Growth Capital Valuation Relative
30. Vaxcyte, Inc. PCVX · breaking out · Too little evidence to rank firmly · 47% evidence 38.2 out of 100 Growth Capital Valuation Relative

Missing figures are not scored as bad. They lower the confidence and pull the final score toward the middle. Relative strength counts only when the company has a reading for this week; with no reading, that factor is left out and its 20 points are shared across the other three in proportion. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led S&P 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step path the industry is placed on (basing, turning, breaking out, leader, fading, asleep), read from how many weeks running it has led S&P 500 and whether that lead is growing or shrinking. It describes where the share price stands, not the direction of earnings, and it is not a recommendation; it is left blank for a company whose weekly history is too short or too stale to read. The figures in this ranking come from the industry comparison: results through the Sep 2026 quarter, and the P/E at that quarter's end. The sections above use the latest weekly price, so a P/E or return there can differ a little from the one here. The stage words in this ranking (such as losing its lead or breaking out) describe the lead over the index, not the price phase in the price section. Related companies: [Biotechnology](https://www.sectoralpha.in/us/sectors/biotechnology), all 30 compared on one page. ## Which companies are close to Insmed in size? Insmed is the 11th largest of 211 Biotechnology companies on Sector Alpha by market value (scores of 4 November 2026). Just above it: Genmab A/S, Roivant Sciences and Incyte Corporation. Just below it: BioNTech SE, Alnylam Pharmaceuticals, Inc. and Exelixis, Inc. ### Biotechnology companies close in size

1. [Genmab A/S](https://www.sectoralpha.in/us/stocks/gmab) $31.9 billion
2. [Roivant Sciences Ltd.](https://www.sectoralpha.in/us/stocks/roiv) $27.6 billion
3. [Incyte Corporation](https://www.sectoralpha.in/us/stocks/incy) $25 billion
4. Insmed Incorporated $24.1 billion
5. [BioNTech SE](https://www.sectoralpha.in/us/stocks/bntx) $22.5 billion
6. [Alnylam Pharmaceuticals, Inc.](https://www.sectoralpha.in/us/stocks/alny) $21.6 billion
7. [Exelixis, Inc.](https://www.sectoralpha.in/us/stocks/exel) $17.8 billion

[All 211 Biotechnology companies, largest first](https://www.sectoralpha.in/us/sectors/biotechnology#all-companies)

### Companies close in size in other industries

1. [STERIS plc](https://www.sectoralpha.in/us/stocks/ste) $24.2 billion · Medical Devices
2. [Roku, Inc.](https://www.sectoralpha.in/us/stocks/roku) $24.2 billion · Entertainment
3. Insmed Incorporated $24.1 billion
4. [T. Rowe Price Group, Inc.](https://www.sectoralpha.in/us/stocks/trow) $24 billion · Asset Management
5. [Markel Group Inc.](https://www.sectoralpha.in/us/stocks/mkl) $23.9 billion · Insurance - Property & Casualty

## What else do people ask about Insmed? ### What were Insmed's latest quarterly results? Insmed Incorporated reported revenue of ₹0.4 B and a net loss of ₹0.0 B for the Jun 2026 quarter. The operating margin was −23.8%, 212.6 percentage points higher than a year earlier (as of 4 November 2026). ### What is Insmed's market cap? Insmed Incorporated's market capitalisation is $24.1 B at a stock price of $110.00. Market cap is the share price times the number of shares, so it changes whenever the price moves (as of 4 November 2026). ### How is Insmed performing? Insmed Incorporated's share price has been falling for 8 weeks. Over the past 13 weeks it has done worse than the S&P 500, for 1 week running. This describes what the data did, not a rating (as of 4 November 2026). ### Will Insmed's stock price go up? This page does not forecast Insmed Incorporated's stock price. What it shows instead: the stock price is $110.00, and it has been falling for 8 weeks. Nobody can reliably say which way a price will move, and this site does not try (as of 4 November 2026). ### What could break the Insmed story? Biggest thing to watch: the price is not yet in a clear uptrend, so timing is the risk more than the business. On price, this page treats a rise as over when the share price closes below its 200-day average on two Fridays in a row (as of 4 November 2026). ### Is Insmed a stock worth studying right now? What the numbers show: Insmed Incorporated's share price, valuation and earnings point in different directions. The next one or two quarters should make it clearer. The main open question: the next one or two quarters of results. Every number on this page is worked out by code from the published figures, with no forecasts and no price opinions (as of 4 November 2026). This is research, not advice. We’re not SEBI-registered.